The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?

被引：52

作者：

Eskens, Ferry A. L. M. ^{[1
]}

Sleijfer, Stefan ^{[1
]}

机构：

[1] Erasmus Univ, Med Ctr, Dept Med Oncol, NL-3000 CA Rotterdam, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2008年 / 44卷 / 16期

关键词：

Bevacizumab; Treatment; Cancer;

D O I：

10.1016/j.ejca.2008.07.042

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bevacizumab is approved for the treatment of colorectal cancer, breast cancer, non-small cell lung cancer and renal cell cancer. Before embracing this expensive agent for many other indications, it remains critical to be aware of the evidence upon which oncologists base their day-to-day clinical practice. In this review, we address the results of clinical studies upon which bevacizumab's current use is based and discuss some future perspectives. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：2350 / 2356

页数：7

共 25 条

[1]

ALLEGRA C, 2008, J CLIN ONCOL S, V26

[2] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study [J].

Burger, Robert A. ;

Sill, Michael W. ;

Monk, Bradley J. ;

Greer, Benjamin E. ;

Sorosky, Joel I. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5165-5171

[3] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer [J].

Cannistra, Stephen A. ;

Matulonis, Ursula A. ;

Penson, Richard T. ;

Hambleton, Julie ;

Dupont, Jakob ;

Mackey, Howard ;

Douglas, Jeffrey ;

Burger, Robert A. ;

Armstrong, Deborah ;

Wenham, Robert ;

McGuire, William .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5180-5186

[4] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].

Escudier, Bernard ;

Pluzanska, Anna ;

Koralewski, Piotr ;

Ravaud, Alain ;

Bracarda, Sergio ;

Szczylik, Cezary ;

Chevreau, Christine ;

Filipek, Marek ;

Melichar, Bohuslav ;

Bajetta, Emilio ;

Gorbunova, Vera ;

Bay, Jacques-Olivier ;

Bodrogi, Istvan ;

Jagiello-Gruszfeld, Agnieszka ;

Moore, Nicola .

LANCET, 2007, 370 (9605) :2103-2111

[5]

FOREROTORRES A, 2008, J CLIN ONCOL S, V26

[6] Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia [J].

Garcia, Agustin A. ;

Hirte, Hal ;

Fleming, Gini ;

Yang, Dongyun ;

Tsao-Wei, Denice D. ;

Roman, Lynda ;

Groshen, Susan ;

Swenson, Steve ;

Markland, Frank ;

Gandara, David ;

Scudder, Sidney ;

Morgan, Robert ;

Chen, Helen ;

Lenz, Heinz-Josef ;

Oza, Amit M. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) :76-82

[7] Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J].

Giantonio, Bruce J. ;

Catalano, Paul J. ;

Meropol, Neal J. ;

O'Dwyer, Peter J. ;

Mitchell, Edith P. ;

Alberts, Steven R. ;

Schwartz, Michael A. ;

Benson, Al B., III .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1539-1544

[8] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[9] Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer [J].

Kabbinavar, F ;

Hurwitz, HI ;

Fehrenbacher, L ;

Meropol, NJ ;

Novotny, WF ;

Lieberman, G ;

Griffing, S ;

Bergsland, E .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :60-65

[10] Addition of bevacizurnab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial [J].

Kabbinavar, FF ;

Schulz, J ;

McCleod, M ;

Patel, T ;

Hamm, JT ;

Hecht, JR ;

Mass, R ;

Perrou, B ;

Nelson, B ;

Novotny, WF .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3697-3705

← 1 2 3 →